Tesamorelin and Body Composition: Evidence from Phase 3 Clinical Trials

Tesamorelin is one of the few peptides with Phase 3 randomised evidence, including a landmark NEJM trial. A physician-led review and how monitored protocols work in Dubai.

By UAE Peptide Clinic Medical Team

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, or GHRH. Rather than introducing growth hormone directly, it acts on the pituitary to stimulate endogenous pulsatile GH release. That distinction matters clinically: pulsatile secretion preserves the physiological rhythm of the GH axis, whereas exogenous GH produces continuous elevation. Research has examined this mechanism extensively, and Tesamorelin is one of the small number of peptides with Phase 3 randomised controlled trial data behind it.

The landmark Phase 3 trial

A Phase 3 randomised controlled trial published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa072375) examined Tesamorelin in patients with excess visceral adipose tissue. Visceral adipose tissue decreased by 15.2 percent in the treatment group, compared with an increase of 5.0 percent in the placebo group. Triglycerides fell by approximately 50 mg/dL in treated patients while rising by around 9 mg/dL in placebo, and the total cholesterol to HDL ratio improved significantly. These are randomised, placebo-controlled findings, which places Tesamorelin in a different evidential category from most peptides discussed in wellness settings.

A 2026 meta-analysis of five randomised controlled trials (DOI: 10.1016/j.orcp.2026.01.002) reported consistent reductions in visceral fat, trunk fat, hepatic fat content and waist circumference. Clinical evidence indicates a reproducible effect on fat distribution in the studied populations.

Mechanism and the IGF-1 axis

• GHRH receptor agonism at the pituitary, stimulating endogenous GH secretion.
• Preservation of pulsatile release rather than continuous GH exposure.
• Downstream IGF-1 elevation, which requires laboratory monitoring during a protocol.
• Effects on lipolysis in visceral adipose tissue specifically, rather than uniform fat loss.
• Interaction with glucose metabolism, which is why fasting glucose and HbA1c are tracked.

Why this is relevant in Dubai

Dubai has a large population of desk-based professionals working long hours in a climate that discourages outdoor activity for much of the year. Visceral adiposity and features of metabolic syndrome are common findings in routine executive screening across the UAE. Research has examined visceral fat as a metabolically active tissue rather than simply stored energy, which is why it attracts clinical attention independently of overall body weight. Tesamorelin is studied in that specific context, not as a general weight-loss agent.

Monitoring is not optional

Because Tesamorelin acts on the GH axis, a physician-supervised protocol includes baseline and interval laboratory work. At UAE Peptide Clinic this typically means IGF-1, fasting glucose, HbA1c and a lipid panel, with review points built into the protocol. Protocols are commonly structured over approximately six months with scheduled reassessment, and are discontinued if laboratory or clinical findings indicate that continuation is inappropriate.

• Baseline bloodwork before the first dose, including IGF-1 and glucose markers.
• Interval monitoring during the protocol rather than unsupervised repeat supply.
• Screening for contraindications including active malignancy and pregnancy.
• Cold-chain pharmaceutical delivery from Dubai to all seven emirates.

Realistic expectations

Tesamorelin has stronger randomised evidence than most peptides, and that evidence was generated in defined patient populations with defined endpoints. Studies have examined visceral fat and lipid parameters; they have not established outcomes for every individual or every goal. Physician assessment is essential, laboratory monitoring is required, and individual outcomes vary.

Tesamorelin is available as a physician-supervised protocol at UAE Peptide Clinic. DHA-registered physician review required. View Tesamorelin Protocol